bluebird bio

bluebird bio

bluebird bio

bluebird bio is developing innovative gene therapies for severe genetic disorders. Our vision is to make the hope of gene therapy a reality.
Founded
1992
Raised
$384.3M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$250,000,000
Post-IPO equity - 2016
$9,300,000
Venture capital - 2012
California Institute for Regenerative Medicine
Team Size
50+
Employees
MedCity News

bluebird bio's stock tanks after report of serious toxicity in sickle cell patient

$250,000,000 Post-IPO equity
Twitter

Boston Business on Twitter

The Motley Fool

Better Buy: Agenus Inc. vs. bluebird bio

The Motley Fool

Why Global Blood Therapeutics Inc. Skyrocketed and bluebird bio Inc. Sank Today

The Motley Fool

Better Buy: bluebird bio vs. Inovio Pharmaceuticals

The Motley Fool

Better Buy: Juno Therapeutics vs. bluebird bio

The Motley Fool

bluebird bio Inc: Catnapping in Cambridge

The Motley Fool

Forget Bluebird Bio, Inc.: These 3 Stocks Are Better Buys

The Motley Fool

bluebird bio, Inc. Takes Flight Towards First Approval

The Motley Fool

Here's Why bluebird bio.'s Stock Tumbled in March

The Motley Fool

Why bluebird bio's Stock Jumped 12.9% on Wednesday

The Motley Fool

Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals

The Motley Fool

Why Bluebird Bio Inc. Plunged Today

The Motley Fool

Why bluebird bio Inc Presented a Lower Price Today

The Motley Fool

Why bluebird bio Inc, Juno Therapeutics Inc, and Alnylam Pharmaceuticals, Inc. Jumped Today

Stock markets
The Motley Fool

Why bluebird bio Inc.'s Stock Dropped 34% in January

Stock markets
The Motley Fool

bluebird bio Inc. Takes Flight

Stock markets Health
The Motley Fool

Why Bluebird Bio Inc.'s Stock Bounced Back --

Stock markets Health
The Motley Fool

Why bluebird bio Inc's Stock Is Tanking Today --

Stock markets Health
The Motley Fool

Here's Why Bluebird Bio Turned in a Disappointing 2015 --